HCV Routes of Transmission: What Goes Around Comes Around

ABSTRACT

The widespread availability of injectable therapies and increase in illicit injection drug use were responsible for the rapid emergence of hepatitis C virus (HCV) infection in the latter half of the 20th century. Iatrogenic exposures and illicit injection drug use have been the predominant risk factors for HCV transmission worldwide. In developing countries, unsafe therapeutic injection practices appear to be responsible for most infections. In developed countries, donor testing has virtually eliminated transfusion-related infections, but infections transmitted to patients by unsafe injections practices is an emerging problem. Injection drug use is the major risk factor for HCV; incidence remains high among new injectors, and this behavior likely contributes to and/or confounds reported associations between HCV-positive persons and histories of noninjection drug use, tattooing, and incarceration. Increased use of illegal drugs also may play a role in the emergence of sexually transmitted HCV infections among HIV-positive men who have sex with men. Ongoing monitoring of the epidemiology of HCV infection is crucial for preventing future infections.

KEYWORDS

HCV - epidemiology - iatrogenic - drug use - sexual

REFERENCES

• 1 Feinstone S M, Kapikian A Z, Purcell R H, Alter H J, Holland P V. Transfusion-associated hepatitis not due to viral hepatitis type A or B.  N Engl J Med. 1975;  292 (15) 767-770
• 2 Mosley J W, Redeker A G, Feinstone S M, Purcell R H. Mutliple hepatitis viruses in multiple attacks of acute viral hepatitis.  N Engl J Med. 1977;  296 (2) 75-78
• 3 Aach R D, Kahn R A. Post-transfusion hepatitis: current perspectives.  Ann Intern Med. 1980;  92 (4) 539-546
• 4 Tabor E, Snoy P, Gerety R J, Wickerhauser M, Menache D, Seeff L B. Transmission of agent of post-transfusion non-A, non-B hepatitis by cryoprecipitate prepared from plasma of symptomless chronic carrier.  Lancet. 1983;  1 (8314-5) 63-64
• 5 Cossart Y E, Kirsch S, Ismay S L. Post-transfusion hepatitis in Australia. Report of the Australian Red Cross study.  Lancet. 1982;  1 (8265) 208-213
• 6 Grillner L, Bergdahl S, Jyrälä A. Non-A, non-B hepatitis after open-heart surgery in Sweden.  Scand J Infect Dis. 1982;  14 (3) 171-175
• 7 Meyers J D, Dienstag J L, Purcell R H, Thomas E D, Holmes K K. Parenterally transmitted non-A, non-B hepatitis: an epidemic reassessed.  Ann Intern Med. 1977;  87 (1) 57-59
• 8 Alter M J, Gerety R J, Smallwood L A et al.. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population.  J Infect Dis. 1982;  145 (6) 886-893
• 9 Alter M J, Coleman P J, Alexander W J et al.. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis.  JAMA. 1989;  262 (9) 1201-1205
• 10 Choo Q L, Weiner A J, Overby L R, Kuo G, Houghton M, Bradley D W. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis.  Br Med Bull. 1990;  46 (2) 423-441
• 11 Alter H J, Purcell R H, Shih J W et al.. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.  N Engl J Med. 1989;  321 (22) 1494-1500
• 12 Kuo G, Choo Q L, Alter H J et al.. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.  Science. 1989;  244 (4902) 362-364
• 13 Alter M J, Margolis H S, Krawczynski K et al.. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.  N Engl J Med. 1992;  327 (27) 1899-1905
• 14 Seeff L B, Buskell-Bales Z, Wright E C et al.. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group.  N Engl J Med. 1992;  327 (27) 1906-1911
• 15 Centers for Disease Control and Prevention . Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease.  MMWR Recomm Rep. 1998;  47 (RR-19) 1-39
• 16 Alter M J. Epidemiology of hepatitis C virus infection.  World J Gastroenterol. 2007;  13 (17) 2436-2441
• 17 Busch M P, Glynn S A, Stramer S L NHLBI-REDS NAT Study Group et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.  Transfusion. 2005;  45 (2) 254-264
• 18 Hladik W, Kataaha P, Mermin J et al.. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors.  Trop Med Int Health. 2006;  11 (6) 951-954
• 19 Hauri A M, Armstrong G L, Hutin Y J. The global burden of disease attributable to contaminated injections given in health care settings.  Int J STD AIDS. 2004;  15 (1) 7-16
• 20 Frank C, Mohamed M K, Strickland G T et al.. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt.  Lancet. 2000;  355 (9207) 887-891
• 21 Perz J F, Thompson N D, Schaefer M K, Patel P R. US outbreak investigations highlight the need for safe injection practices and basic infection control.  Clin Liver Dis. 2010;  14 (1) 137-151, x
• 22 Alter M J. Healthcare should not be a vehicle for transmission of hepatitis C virus.  J Hepatol. 2008;  48 (1) 2-4
• 23 Centers for Disease Control and Prevention (CDC) . Transmission of hepatitis B and C viruses in outpatient settings—New York, Oklahoma, and Nebraska, 2000-2002.  MMWR Morb Mortal Wkly Rep. 2003;  52 (38) 901-906
• 24 Desenclos J C, Bourdiol-Razès M, Rolin B et al.. Hepatitis C in a ward for cystic fibrosis and diabetic patients: possible transmission by spring-loaded finger-stick devices for self-monitoring of capillary blood glucose.  Infect Control Hosp Epidemiol. 2001;  22 (11) 701-707
• 25 Krause G, Trepka M J, Whisenhunt R S et al.. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials.  Infect Control Hosp Epidemiol. 2003;  24 (2) 122-127
• 26 Germain J M, Carbonne A, Thiers V et al.. Patient-to-patient transmission of hepatitis C virus through the use of multidose vials during general anesthesia.  Infect Control Hosp Epidemiol. 2005;  26 (9) 789-792
• 27 Thompson N D, Perz J F, Moorman A C, Holmberg S D. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008.  Ann Intern Med. 2009;  150 (1) 33-39
• 28 Phillips L D. History of I.V. therapy. In: Davis F A, ed. Manual of I.V. Therapeutics. Philadelphia; 1993: 1-10
• 29 Des Jarlais D C, Diaz T, Perlis T et al.. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City.  Am J Epidemiol. 2003;  157 (5) 467-471
• 30 Hagan H, Des Jarlais D C, Stern R et al.. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection.  Int J Drug Policy. 2007;  18 (5) 341-351
• 31 Thorpe L E, Ouellet L, Hershow R, Bailey S, Williams I, Monerosso E. The multiperson use of non-syringe injection equipment and risk of hepatitis c infection in a cohort of young adult injection drug users, Chicago 1997–1999.  Ann Epidemiol. 2000;  10 (7) 472-473
• 32 Thorpe L E, Ouellet L J, Hershow R et al.. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment.  Am J Epidemiol. 2002;  155 (7) 645-653
• 33 Burt R D, Hagan H, Garfein R S, Sabin K, Weinbaum C, Thiede H. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18–30 years, 1994–2004.  J Urban Health. 2007;  84 (3) 436-454
• 34 Hahn J A, Page-Shafer K, Lum P J et al.. Hepatitis C virus seroconversion among young injection drug users: relationships and risks.  J Infect Dis. 2002;  186 (11) 1558-1564
• 35 Kamili S, Krawczynski K, McCaustland K, Li X, Alter M J. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature.  Infect Control Hosp Epidemiol. 2007;  28 (5) 519-524
• 36 Hagan H, Pouget E R, Des Jarlais D C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.  J Infect Dis. 2011;  204 (1) 74-83
• 37 Terrault N A. Sexual activity as a risk factor for hepatitis C.  Hepatology. 2002;  36 (5, Suppl 1) S99-S105
• 38 Tohme R A, Holmberg S D. Is sexual contact a major mode of hepatitis C virus transmission?.  Hepatology. 2010;  52 (4) 1497-1505
• 39 Alter M J, Kruszon-Moran D, Nainan O V et al.. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.  N Engl J Med. 1999;  341 (8) 556-562
• 40 Hagan H, Snyder N, Hough E et al.. Case-reporting of acute hepatitis B and C among injection drug users.  J Urban Health. 2002;  79 (4) 579-585
• 41 Robotin M C, Copland J, Tallis G et al.. Surveillance for newly acquired hepatitis C in Australia.  J Gastroenterol Hepatol. 2004;  19 (3) 283-288
• 42 Spada E, Mele A, Ciccozzi M SEIEVA collaborating group et al. Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy.  Dig Liver Dis. 2001;  33 (9) 778-784
• 43 Alter M J, Hadler S C, Judson F N et al.. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection.  JAMA. 1990;  264 (17) 2231-2235
• 44 Williams I T, Bell B P, Kuhnert W, Alter M J. Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006.  Arch Intern Med. 2011;  171 (3) 242-248
• 45 Armstrong G L, Alter M J, McQuillan G M, Margolis H S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States.  Hepatology. 2000;  31 (3) 777-782
• 46 Aach R D, Szmuness W, Mosley J W et al.. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: the transfusion-transmitted viruses study.  N Engl J Med. 1981;  304 (17) 989-994
• 47 Alter H J, Holland P V. Indirect tests to detect the non-A, non-B hepatitis carrier state.  Ann Intern Med. 1984;  101 (6) 859-861
• 48 Donahue J G, Muñoz A, Ness P M et al.. The declining risk of post-transfusion hepatitis C virus infection.  N Engl J Med. 1992;  327 (6) 369-373
• 49 Busch M P, Glynn S A, Wright D J National Heart, Lung, Blood Institute Nucleic Acid Test Study Group* et al. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection.  Transfusion. 2005;  45 (12) 1853-1863
• 50 Kleinman S H, Stramer S L, Brodsky J P, Caglioti S, Busch M P. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms.  Transfusion. 2006;  46 (5) 695-702
• 51 Sharma U K, Stramer S L, Wright D J Retrovirus Epidemiology Donor Study et al. Impact of changes in viral marker screening assays.  Transfusion. 2003;  43 (2) 202-214
• 52 Zou S, Dorsey K A, Notari E P et al.. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing.  Transfusion. 2010;  50 (7) 1495-1504
• 53 Zou S, Notari IV E P, Stramer S L, Wahab F, Musavi F, Dodd R Y. ARCNET Research Group . Patterns of age- and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995 to 2002: American Red Cross blood donor study.  Transfusion. 2004;  44 (11) 1640-1647
• 54 Armstrong G L. Injection drug users in the United States, 1979-2002: an aging population.  Arch Intern Med. 2007;  167 (2) 166-173
• 55 Sun C A, Chen H C, Lu S N et al.. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors.  J Med Virol. 2001;  65 (1) 30-34
• 56 Okayama A, Stuver S O, Tabor E et al.. Incident hepatitis C virus infection in a community-based population in Japan.  J Viral Hepat. 2002;  9 (1) 43-51
• 57 Fukuizumi K, Sata M, Suzuki H, Nakano H, Tanikawa K. Hepatitis C virus seroconversion rate in a hyperendemic area of HCV in Japan: a prospective study.  Scand J Infect Dis. 1997;  29 (4) 345-347
• 58 Buffington J, Murray P J, Schlanger K et al.. Low prevalence of hepatitis C virus antibody in men who have sex with men who do not inject drugs.  Public Health Rep. 2007;  122 (Suppl 2) 63-67
• 59 Urbanus A T, van de Laar T J, Stolte I G et al.. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic.  AIDS. 2009;  23 (12) F1-F7
• 60 Fierer D S, Factor S H, Uriel A J Centers for Disease Control and Prevention (CDC) et al. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men—New York City, 2005-2010.  MMWR Morb Mortal Wkly Rep. 2011;  60 (28) 945-950
• 61 van de Laar T J, Pybus O, Bruisten S et al.. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men.  Gastroenterology. 2009;  136 (5) 1609-1617
• 62 van de Laar T J, Matthews G V, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection.  AIDS. 2010;  24 (12) 1799-1812
• 63 Taylor L E, Holubar M, Wu K et al.. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials.  Clin Infect Dis. 2011;  52 (6) 812-818
• 64 Spradling P R, Richardson J T, Buchacz K HIV Outpatient Study Investigators et al. Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007.  J Acquir Immune Defic Syndr. 2010;  53 (3) 388-396
• 65 Alter M J. Prevention of spread of hepatitis C.  Hepatology. 2002;  36 (5, Suppl 1) S93-S98
• 66 Hwang L Y, Kramer J R, Troisi C et al.. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population.  Hepatology. 2006;  44 (2) 341-351
• 67 Arcari C M, Alter M J. Controversies in HCV transmission: from tattoos to barbershops. In: Hot Topics in Viral Hepatitis. FB Communications, Rome; 2008. 11: 19-27
• 68 Santayana G. Life of Reason, Reason in Common Sense. New York: Scribner's; 1905: 284. Available at: http://iat.iupui.edu/santayana/content/santayana-quotations Accessed October 5, 2011